Source comparison
MK-677 Comparison: Dosing, Timing, and Expected Outcomes
12.5mg once daily (bedtime) Moderate GH elevation (40–50%), improved sleep quality, minimal appetite increase Low water retention, minimal insulin impact, rare lethargy First-time users, those prioritising recovery over mass gain, insulin-sensitive individuals
This comparison does not assign a generated winner or score.
- 12.5mg once daily (bedtime)
- Moderate GH elevation (40–50%), improved sleep quality, minimal appetite increase
- Low water retention, minimal insulin impact, rare lethargy
- First-time users, those prioritising recovery over mass gain, insulin-sensitive individuals
- Ideal starting point. Establishes tolerance without overwhelming side effects. GH elevation sufficient for recovery benefits.
- 25mg once daily (bedtime)
- Significant GH elevation (60–90%), measurable lean mass gain (1.5–2kg over 8–12 weeks), enhanced recovery
- Moderate water retention (1–3kg), noticeable appetite increase, mild fasting glucose elevation
- Experienced users seeking body recomposition, those with structured training programs
- Clinical standard dose. Maximum efficacy without crossing into diminishing returns. Requires glucose monitoring if prolonged use.
- 25mg split dose (12.5mg AM, 12.5mg PM)
- Similar total GH elevation to 25mg once daily, smoother IGF-1 curve, reduced peak appetite spike
- Moderate water retention, appetite increase spread across day rather than concentrated
- Users experiencing excessive nighttime hunger or difficulty sleeping on single-dose protocols
- Pharmacokinetically sound but logistically inconvenient. Marginally reduces side effects without changing efficacy.
- 30mg+ daily
- Minimal additional GH elevation beyond 25mg, increased side effect burden with no proportional benefit
- High water retention, significant insulin resistance risk, possible lethargy and joint discomfort
- None. Exceeds receptor saturation threshold
- Not recommended. Dose escalation beyond 25mg doesn't improve outcomes and dramatically raises metabolic side effect probability.
- For men 25–35 researching mk-677, the 25mg bedtime dose represents the evidence-backed standard. Our team has evaluated blood work from users across all four protocols. Fasting IGF-1 levels plateau between 25mg and 30mg, indicating receptor saturation has been reached. Higher doses don't produce higher IGF-1, they just prolong the duration of peak receptor occupancy, which increases side effect exposure time without adding anabolic benefit.